{"id":"c-e-r-a","safety":{"commonSideEffects":[{"rate":"10%","effect":"Nausea"},{"rate":"8%","effect":"Headache"},{"rate":"6%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4298075","moleculeType":"Small molecule"},"_fixedAt":"2026-03-30T16:53:46.704639","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by continuously activating the erythropoietin receptor, which stimulates erythropoiesis.","oneSentence":"C.E.R.A. is a continuous erythropoietin receptor activator.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:59:03.348Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"}]},"_fixedFields":["pubmed(78)"],"trialDetails":[{"nctId":"NCT00661388","phase":"PHASE3","title":"A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-08","conditions":"Anemia","enrollment":75},{"nctId":"NCT00642967","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-06","conditions":"Anemia","enrollment":127},{"nctId":"NCT00717821","phase":"PHASE3","title":"A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-08","conditions":"Anemia","enrollment":421},{"nctId":"NCT01191983","phase":"PHASE4","title":"A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-08-13","conditions":"Anemia","enrollment":102},{"nctId":"NCT00642304","phase":"PHASE3","title":"A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-03-27","conditions":"Anemia","enrollment":20},{"nctId":"NCT00360347","phase":"PHASE1, PHASE2","title":"A Study of Mircera in Anemic Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2001-11-29","conditions":"Anemia","enrollment":""},{"nctId":"NCT00661505","phase":"PHASE3","title":"A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-05-14","conditions":"Anemia","enrollment":132},{"nctId":"NCT01342640","phase":"PHASE4","title":"A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-07-18","conditions":"Anemia","enrollment":70},{"nctId":"NCT01677767","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Chronic Kidney Disease Patients on Dialysis With Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-04-30","conditions":"Anemia","enrollment":127},{"nctId":"NCT00737477","phase":"PHASE3","title":"A Study of Monthly Subcutaneous (SC) Mircera for Maintenance Treatment of Participants With Chronic Kidney Disease on Peritoneal Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-09-30","conditions":"Anemia","enrollment":96},{"nctId":"NCT01194154","phase":"PHASE2","title":"A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-09-30","conditions":"Kidney Disease, Chronic","enrollment":241},{"nctId":"NCT00576628","phase":"PHASE3","title":"A Study of Subcutaneous C.E.R.A. for the Treatment of Anemia in Pre-Dialysis Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-05","conditions":"Anemia","enrollment":133},{"nctId":"NCT01974271","phase":"","title":"An Observational Study of Hemoglobin Stability in Chronic Kidney Disease Patients on Dialysis Treated With Mircera (Methoxy Polyethylene Glycol-epoetin Beta)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01","conditions":"Anemia","enrollment":661},{"nctId":"NCT01892202","phase":"","title":"A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Not on Dialysis","status":"NO_LONGER_AVAILABLE","sponsor":"Hoffmann-La Roche","startDate":"2011-02","conditions":"Anemia","enrollment":""},{"nctId":"NCT00882713","phase":"PHASE3","title":"A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-02","conditions":"Anemia","enrollment":202},{"nctId":"NCT00545571","phase":"PHASE3","title":"MIRACLE Study: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Anemia","enrollment":120},{"nctId":"NCT00642850","phase":"PHASE3","title":"STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-11","conditions":"Anemia","enrollment":188},{"nctId":"NCT01695746","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-08","conditions":"Anemia","enrollment":108},{"nctId":"NCT00517881","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of Subcutaneous C.E.R.A. in Pre-Dialysis Participants With Chronic Renal Anemia","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-06","conditions":"Anemia","enrollment":29},{"nctId":"NCT00576303","phase":"PHASE3","title":"A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-04","conditions":"Anemia","enrollment":200},{"nctId":"NCT00605293","phase":"PHASE3","title":"A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Anemia","enrollment":101},{"nctId":"NCT00517413","phase":"PHASE3","title":"LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Anemia","enrollment":163},{"nctId":"NCT00699348","phase":"PHASE3","title":"A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-07","conditions":"Anemia","enrollment":351},{"nctId":"NCT00559637","phase":"PHASE3","title":"A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Anemia","enrollment":184},{"nctId":"NCT00773968","phase":"PHASE3","title":"A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-09","conditions":"Anemia","enrollment":140},{"nctId":"NCT00550680","phase":"PHASE3","title":"A Study of Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Chronic Renal Anemia","enrollment":208},{"nctId":"NCT00660023","phase":"PHASE3","title":"A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-08","conditions":"Anemia","enrollment":124},{"nctId":"NCT01666301","phase":"NA","title":"ESAs, Reticulocyte Dynamic and Hemoglobin Variability","status":"COMPLETED","sponsor":"Ospedale Regionale di Locarno","startDate":"2010-02","conditions":"Erythropoiesis Stimulating Agent Pharmacodynamics","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":78,"recentPublications":[{"date":"2025 Nov","pmid":"40662229","title":"Pharmacokinetic and pharmacodynamic modelling of continuous erythropoiesis receptor activator in children: A comprehensive analysis and real-world data validation.","journal":"British journal of clinical pharmacology"},{"date":"2024","pmid":"37708860","title":"Continuous Erythropoietin Receptor Activator for the Treatment of Chronic Dialysis Patients with Renal Anemia in Daily Clinical Practice in Poland: A Non-Interventional, Multi-Center, Pragmatic NAVIGO Trial.","journal":"Nephron"},{"date":"2024 Mar","pmid":"37566114","title":"Real-world evidence on the dosing and safety of C.E.R.A. in pediatric dialysis patients: findings from the International Pediatric Dialysis Network registries.","journal":"Pediatric nephrology (Berlin, Germany)"},{"date":"2023 Jun","pmid":"36587890","title":"Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.","journal":"American journal of kidney diseases : the official journal of the National Kidney Foundation"},{"date":"2021","pmid":"32829322","title":"Prolonged Duration of Erythropoiesis-Stimulating Agents' Action Delays Disease Progression in Anti-Thy 1 Antibody-Induced Chronic Glomerulonephritis Rats.","journal":"Pharmacology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"C.E.R.A.","genericName":"C.E.R.A.","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"C.E.R.A. is a continuous erythropoietin receptor activator. Used for Anemia associated with chronic kidney disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}